Skip to main content

CSL Behring Plasma Academy

CSL Behring, which makes medicines for rare bleeding disorders, recently hosted hematology/oncology fellows at an in-person learning event in the Chicago area.

CSL Plasma Academy

Driven by its promise to patients, CSL Behring recently held its second annual Plasma Academy for health care professionals, an opportunity to take a deep dive into benign hematology. The recent, two-day interactive education program, offered in collaboration with the Versiti Blood Research Institute, hosted 11 hematology/oncology fellows from across the United States.

Benign hematology includes noncancerous conditions in which the blood does not function normally. Those conditions, which can be inherited or acquired over time, include hemophilia, von Willebrand disease, other factor deficiencies and platelet disorders.

“This event is focused on supporting education for trainees interested in pursuing a career in benign hematology,” said Vidhi Desai, Senior Medical Director at CSL Behring. “While this was our second Plasma Academy, it was the first one held in person and we were happy to see the open discussions and sharing of ideas that took place. It was great to see attendees being able to connect with one another as well as the faculty.”

This year’s academy included presentations and expert-led, case-based discussion on topics such asinherited bleeding disorders, platelet disorders, laboratory hematology and transfusion medicine, among others. In addition, the agenda included a career trajectory panel discussion, peer-to-peer case study discussions, a tour of a CSL Behring manufacturing facility as well as networking opportunities.

The next annual Plasma Academy will be scheduled for late spring 2024. Get more information about medical education opportunities from CSL Behring, a business unit of global biotech company CSL.